As a tissue that exhibits rapid cyclical growth and shedding throughout the reproductive life of the female, human endometrium provides a good model for the study of normal physiological angiogenesis. The objective of this paper is to summarize recent data on endometrial vascular growth, present new data on regional variability in endothelial cell proliferation within the endometrium, and interpret this information in light of current knowledge of the mechanisms by which angiogenesis occurs. Conventional angiogenesis normally involves a series of steps which include endothelial cell activation, breakdown of the basement membrane, migration and proliferation of the endothelial cell, fusion of sprouts, and tube formation. Other mechanisms by which angiogenesis occurs include intussusception and vessel elongation. Using immunohistochemical techniques we have shown repeatedly that levels of endothelial cell proliferation within human endometrium do not show any consistent pattern across the different stages of the menstrual cycle, which is unexpected since significant vascular growth must occur during the proliferative phase, when the endometrium increases in thickness by up to 4-fold. There are two possible explanations for this; either there is no obligatory link between endometrial endothelial cell proliferation and new vessel formation, or there is significant variation in endothelial cell proliferation within different regions of the same uterus. Multiple samples from hysterectomy specimens subsequently demonstrated that the variability is due to real differences between individuals, as well as showing that the endothelial cell proliferation index is significantly elevated in functionalis compared with basalis. During these studies we observed that endothelial cell proliferation nearly always appeared inside existing endometrial vessels, rather than be associated with structures that could be identified as vascular sprouts. To explore further whether sprout formation occurs during endometrial angiogenesis, we investigated the immunohistochemical distribution of integrin α v β 3 on endometrial endothelial cells. As for endothelial cell proliferation, integrin α v β 3 immunostaining was seen only on endothelial cells that appeared within existing blood vessels. The results from these studies have major implications for our understanding of the mechanisms that control endometrial angiogenesis.
Introduction
As a tissue that exhibits rapid cyclical growth and shedding throughout the reproductive life of the female, human endometrium provides a good model for the study of normal physiological angiogenesis. Most adult vascular beds maintain very constant structure and function throughout life, apart from pathological situations such as wound healing and solid tumour growth. Despite the regular, physiologically normal angiogenesis that occurs in the female reproductive tract throughout much of adult life, very little has been published on endometrial angiogenesis. In some of the studies published to date, it has been reported that angiogenesis plays a role in the cessation of menstruation as the vascular bed repairs itself (Markee, 1940) , and that there is an increase (not statistically proven) in endothelial cell proliferation during the early to mid part of the proliferative phase (Ferenczy et al., 1979) . It should also be noted, however, that Ferenczy et al. (1979) reported elevated levels of endothelial cell proliferation at all stages of the menstrual cycle, with highest levels of proliferation in the upper third of the functionalis and lowest levels in the basalis, and no reported regional variability within the corpus and fundus (data to support this last statement were not given). Other evidence to support angiogenesis during the secretory phase of the cycle has also been reported based on endothelial cell proliferation studies of spiral arterioles in rhesus monkeys (Kaiserman-Abramof and Padykula, 1989) . In recent times our laboratory has published a number of studies investigating the mechanisms by which vascular growth occurs in human endometrium. The objective of this paper is to summarize this information on endometrial vascular growth, present new data on regional variability in endothelial cell proliferation within the endometrium, and to interpret these results in light of current knowledge on the mechanisms by which angiogenesis occurs.
Mechanisms of angiogenesis
Angiogenesis is defined as the process whereby new blood vessels are created from pre-existing vasculature. The conventional understanding is that this process involves a number of steps which include activation of endothelial cells (EC) within the existing vessel, breakdown of the basement membrane, migration of the EC towards a stimulus, proliferation of the EC, fusion of two sprouts to form a continuous line of EC, tube formation, and recommencement of blood flow (Klagsbrun and D'Amore 1991) . Variations on these steps for new blood vessel formation have also been described; for example, it has been shown that vascular sprouting can occur without proliferation of EC or vice versa (Ausprunk et al., 1974; Sholley et al., 1984; Nagy et al., 1995; Vernon et al., 1995) . However, in addition to angiogenesis by sprouting, it is now increasingly recognized that other mechanisms exist for the creation of new blood vessels from the existing vasculature. Two such processes are intussusception (Burri and Tarek, 1990 ) and vessel elongation (Ausprunk et al., 1974) . Intussusception has been defined as growth by 'deposition of new particles or pieces of formative material among those already embodied in a tissue or structure'. In vascular tissue this can occur when a vessel is divided internally by a wall of EC, splitting the lumen of the vessel into two. Subsequent remodelling of the vessel wall can result in two new vessels running parallel to each other. This method of creating new vessels has the advantage that the vessel wall is never breached, and blood flow can continue throughout the whole process. Elongation (and vessel widening) probably occurs commonly in growing tissues as existing vessels constantly restructure in response to the metabolic demands of the surrounding cells. As with intussusception, elongation has the advantage that the vessel wall is not breached, and blood flow is continuous throughout the whole process.
While conventional sprout-forming angiogenesis normally involves a series of steps which include EC activation, breakdown of the basement membrane, migration and proliferation of the EC, fusion of sprouts and tube formation, angiogenesis by intussusception or vessel elongation does not necessarily include each of these steps. While detailed information on the cellular processes involved in each of these latter two angiogenic mechanisms is lacking, it would seem likely that EC proliferation will be a key component in most angiogenic events, regardless of the other steps involved in new vessel formation. We have therefore used EC proliferation as a marker for angiogenesis in many of our studies, assuming that it will identify new vessel growth regardless of the angiogenic mechanisms involved.
Studies on endometrial endothelial cell proliferation
For all studies on EC proliferation in human endometrium we have used a double immunohistochemical staining protocol on formalin-fixed, paraffin-embedded specimens. We have validated this protocol using bromodeoxyuridine incorporation [Goodger (Macpherson) and Rogers, 1994] and found good agreement between the two methods. In brief, sections are dewaxed, rehydrated and blocked for endogenous peroxidase with 3% H 2 O 2 (in methanol) for 10 min at 37°C. They are then incubated at 37°C for 60 min with anti-proliferating cell nuclear antigen (PCNA) diluted 1/50 in 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), followed by incubation at room temperature with biotinylated rabbit anti-mouse immunoglobulin (Ig), horseradish peroxidase-streptavidin conjugate and aminoethyl carbazole (AEC) red chromogen. Sections are treated with double-staining enhancer for 30 min at room temperature and then incubated at 37°C for 60 min with anti-CD34 diluted 1/50 in 1% BSA in PBS. This is followed by biotinylated rabbit anti-mouse Ig, alkaline phosphatase-streptavidin conjugate and alkaline phosphatase-blue (AP-blue) chromogen, all at room temperature. Proliferating EC are thus identified as cells with blue cytoplasm and red nuclei. Total EC numbers in a section are calculated from a serial section single-immunostained for CD34 alone and counterstained with haematoxylin to visualize all EC nuclei. This information then enables an EC proliferation index to be calculated. Endometria are also dated according to standard histological criteria (Noyes et al., 1950) . Quantification of proliferating EC uses image analysis techniques where threshold levels for colour intensity for PCNA staining can be standardized.
Using this immunohistochemical technique we have shown repeatedly that levels of EC proliferation within human endometrium do not show any consistent pattern across the different stages of the menstrual cycle [Goodger (Macpherson) and Rogers, 1994; Wingfield et al., 1995; Kooy et al., 1996] . Composite data for 81 different control women taken from the three studies quoted above are shown in Figure 1A . The lack of a menstrual cycle stage-related pattern is highly unexpected since it appears certain that significant vascular growth must occur during the proliferative phase of the cycle, when the endometrium increases in thickness by up to 4-fold in the space of a few days. However, it is not unusual for women from the same stage of the menstrual cycle to have endometrial endothelial cell proliferation rates that vary from between 0% and 30%. It should be noted that significant rates of endothelial cell proliferation are also seen at stages of the cycle when endometrial growth is minimal, such as late-secretory and menstrual.
It also appears that elevated EC proliferation rates correlate with endometrial-related disorders such as endometriosis (Wingfield et al., 1995) and menorrhagia (Kooy et al., 1996) . Composite data from these two publications showing EC proliferation rates for women with endometriosis and menorrhagia are shown in Figure  1B . In both studies there were significant elevations in EC proliferation rates compared with controls, with most of this increase occurring during the early to mid proliferative stages of the cycle.
There are two possible explanations for the high variability in endothelial cell proliferation rates seen between endometria from women at similar stages of the menstrual cycle. The first is that there is no obligatory link between endometrial endothelial cell proliferation and new vessel formation or new tissue growth in the endometrium. In other words, the different steps of the angiogenic process Rogers, 1994; Wingfield et al., 1995; Kooy et al., 1996] . Bars show median values for each cycle stage. Cycle stages: 1 = menstrual, 2 = early proliferative, 3 = early-mid proliferative, 4 = mid proliferative, 5 = mid-late proliferative, 6 = late proliferative, 7 = early secretory, 8 = mid secretory, 9 = late secretory. (B) As for (A), but showing endometrial endothelial cell proliferation data from women with endometriosis (Wingfield et al., 1995) or menorrhagia (Kooy et al., 1996) . Menstrual cycle stages as in (A).
do not have to occur concurrently during vessel growth in the endometrium. The second explanation is that there is significant variation in endothelial cell proliferation within different regions of the same uterus. Since each of the original studies [Goodger (Macpherson) and Rogers, 1994; Wingfield et al., 1995; Kooy et al., 1996] was based on a single endometrial biopsy per subject, this might explain the wide variability from subject to subject.
We have subsequently tested the hypothesis that regional variability in EC proliferation within individual endometria was responsible for the wide variation seen between women, by evaluating multiple samples from the same uteri. In this study we used endometrial tissues from 13 hysterectomy specimens to measure regional variability in endometrial EC proliferation and to look for differences in EC proliferation rates between the basalis and the functionalis. Functionalis was defined as a field adjacent to the surface epithelium and basalis as a field adjacent to the myometrium.
The results from this study (Table I) showed the same high degree of variability in endometrial EC proliferation rates between women as seen in earlier studies [Goodger (Macpherson) and Rogers, 1994; Wingfield et al., 1995; Kooy et al., 1996] . A one-way analysis of variance performed on the functionalis data showed that the variability in endometrial EC proliferation index in this layer was significantly higher between individuals than within a single uterus (F = 5.32, P = 0.002). Using the interclass correlation coefficient, it was determined that 84% of variability came from differences between individuals and 16% from variability within. In contrast to the functionalis, the basalis data showed within-uterus variability in EC proliferation index to be similar to the variability seen between uteri from different individuals (F = 2.03, P = 0.09). Endothelial cell proliferation indices were significantly higher in the functionalis (mean 7.1%) than the basalis (mean 1.5%) (P = 0.001). This study therefore demonstrated that variability in endometrial EC proliferation index between different women is due to real differences between individuals rather than to regional variability within uteri. It also showed that the EC proliferation index is significantly elevated in functionalis compared with basalis. Taken together with results from the earlier studies in our laboratory using single biopsies from large groups of women at all stages of the menstrual cycle [Goodger (Macpherson) and Rogers, 1994; Wingfield et al., 1995; Kooy et al., 1996] , these findings have major implications for our understanding of how angiogenesis occurs in the endometrium, and the possible mechanisms by which it might be controlled.
Given that the major growth in endometrial thickness occurs during the proliferative phase of the menstrual cycle, and given that it has been reported that endometrial vascular density remains unchanged throughout the cycle (Rogers et al., 1993) , it seems reasonable to assume that significant vascular growth or angiogenesis must occur during the proliferative phase of the cycle. However, our results now confirm that EC proliferation, one of the key steps in the angiogenic process, occurs throughout the menstrual cycle, with no statistically significant elevation at any particular stage. The most obvious interpretation of these data is that new vessel growth and EC proliferation do not always occur at the same time in endometrium.
There are other explanations for the data in this study which suggest that EC proliferation and angiogenesis may occur concurrently. The first of these is based on the wide variability seen between women in levels of endometrial EC proliferation index. It is possible that if individual women were tracked longitudinally throughout the menstrual cycle, a regular pattern of EC proliferation would be detected, with a peak in the proliferative phase at the time of maximum vessel growth. However, this would still not explain the very high levels of EC proliferation seen in some women at times of the cycle when no endometrial growth is occurring. Another possible explanation is that the endometrial vasculature is remodelling rather than growing. Such remodelling could involve relatively high levels of EC turnover, with high levels of EC proliferation and cell death (either through apoptosis or shedding into the bloodstream).
Vascular sprouts and endometrial angiogenesis
Based on these EC proliferation studies we hypothesized that angiogenesis in human endometrium may not occur via the classical steps of basement membrane breakdown, EC migration and proliferation, sprout formation and subsequent tube formation (Goodger-Macpherson and Rogers, 1995) . This statement is based on the observation that proliferating EC nearly always appeared inside existing endometrial vessels, rather than associated with structures that could be identified as vascular sprouts. By contrast, similar immunohistochemical techniques used on ovarian tissues clearly demonstrated vascular sprouts in the pre-ovulatory follicle and proliferating EC associated with sprout-like structures during vascularization of the corpus luteum. This evidence neither proves nor disproves the mechanism by which new vessels are formed in the endometrium; however, it does clearly identify the need for more information on endometrial angiogenesis and the mechanisms by which it occurs.
To explore further whether sprout formation occurs during endometrial angiogenesis, we have investigated the immunohistochemical distribution of integrin α v β 3 on endometrial EC (Hii and Rogers, 1998) . Integrin α v β 3 is a heterodimer, glycoprotein adhesion molecule found on many cell types, including EC, and is known to bind at least seven different ligands; vitronectin, fibrinogen, von Willebrand factor, fibronectin, thrombospondin, laminin and thrombin (Dejana et al., 1993; Luscinskas and Fawler, 1994) . Recent studies have shown that the ligation of integrin α v β 3 was required for the survival and maturation of newly formed blood vessels, with expression increasing 4-fold during angiogenesis on chick chorionallantoic membrane (Brooks et al., 1994a) . Growth of new blood vessels induced by basic fibroblast growth factor (b-FGF), tumour necrosis factor-α (TNF-α) and human melanoma fragments is blocked by monoclonal antibody (mAb) to α v β 3 , but this mAb has no effect on pre-existing vessels (Brooks et al., 1994b; Friedlander et al., 1995) . Other studies also support a role for integrin α v β 3 as an angiogenic marker. Sepp et al. (1994) have shown that the expression of α v β 3 integrin on human microvascular EC could be increased by b-FGF. Enenstein and Kramer, 1994) documented that α v subunit concentration, which is normally low in the microvasculature, is increased on angiogenic vascular sprouts.
Archival, formalin-fixed, paraffin-embedded endometrial tissue blocks (n = 24) were used in this study. Endometria were grouped histologically into eight stages of the menstrual cycle according to the criteria of Noyes et al. (1950) . Following dewaxing, formalin-fixed sections underwent antigen retrieval in 0.1 M trisodium citrate buffer at room temperature for 2 h, followed by quenching, blocking and an overnight incubation with anti-integrin α v β 3 antibody (clone LM609). Total vessel numbers were calculated from serial sections stained with antibody to EC marker CD34. Endothelial expression of integrin α v β 3 was predominantly cytoplasmic, with varying numbers of EC within different vessel profiles staining positively for α v β 3 . Structures which might have been vascular sprouts were not observed in any endometrial tissues, despite being seen in ovarian tumour sections subjected to the same immunohistochemical analysis. As for EC proliferation data discussed earlier, there was no evidence for differences in EC expression of α v β 3 at different stages of the menstrual cycle.
The results from this study provide further support for the hypotheses that angiogenesis is occurring continuously throughout the menstrual cycle in human endometrium, and that this happens without the formation of vascular sprouts. Throughout this study, integrin α v β 3 immunostaining was only seen on EC that appeared to be within existing blood vessels. While it is not possible to state conclusively from these results that vascular sprouts do not occur during angiogenesis in human endometrium, it seems highly improbable that integrin α v β 3 , a marker that localizes specifically to vascular sprouts in other tissues (Enenstein and Kramer, 1994) will stain blood vesselsbut not sprouts-in endometrium. Further support for the idea that there are no vascular sprouts in endometrium was provided by the ready identification of sprout-like structures using integrin α v β 3 in ovarian tumour tissue, in contrast to their complete absence using the same immunostaining protocol in endometrium.
Within a blood vessel which is growing by elongation and expansion, there is presumably a need for EC to migrate as vascular remodelling occurs. Integrin α v β 3 has been shown to have a role in vascular basement membrane breakdown and its expression is transient (Brooks et al., 1996) . In the present study it was observed that only some vessels expressed α v β 3 while others did not, and that not all EC within a vessel were positive. It is possible that vessels which expressed integrin α v β 3 were growing lengthways or widthways, while those that did not express α v β 3 remained dormant. More specifically it is possible that, within a growing vessel, some EC are involved in the remodelling process and some are quiescent.
Conclusions
The results from these studies have major implications for our understanding of the mechanisms that control endometrial angiogenesis. The lack of correlation between menstrual cycle stage and EC proliferation index, or EC expression of integrin α v β 3 , suggests that vascular growth is not under the overall control of oestrogen and progesterone. This would make vascular growth unusual in terms of endometrial physiology, since nearly every other aspect of endometrial growth and function appears to be driven by the sex steroids. In addition to this, any future putative models for the control of endometrial angiogenesis will need to incorporate separate promoters or inhibitors for each of the different steps of the angiogenic process, and to take account of the possibility that new vessel growth is occurring by elongation and intussusception as well as sprout formation.
To date, studies on endometrial expression of angiogenic growth factors such as vascular endothelial growth factor (VEGF) have all tried to identify a correlation between menstrual cycle stage and expression (Charnock-Jones et al., 1993; Li et al., 1994; Torrey et al., 1996) , an approach which in hindsight now appears unlikely to give meaningful results (at least in the understanding of endometrial angiogenesis). In addition, these studies have not looked for differences between functionalis and basalis, an issue which will have to be considered in the future since we have shown that angiogenesis is controlled differently in these two endometrial regions.
